News

'Offer smears to women with lesion history for 25 years'

31-Oct-07

Women should be offered annual smear tests for at least 25 years after treatment for pre-cancerous lesions, say Swedish researchers.
The latest study findings indicate that women are still at risk of developing invasive cancer of the cervix even after treatment for grade three cervical intraepithelial neoplasmia.

The findings emphasise the need for regular screening even beyond the age of 60, say the researchers.

For the study, the research team examined data from the National Swedish Cancer Register. This included information on 132,493 women, recorded between 1958 and 2002, who had a diagnosis of severe dysplasia.

Using patient registration numbers, the researchers identified that 881 women had a diagnosis of invasive cervical cancer and 111 women had a diagnosis of vaginal cancer more than one year after undergoing treatment for severe dysplasia.

They also found an increased risk of cervical cancer in women who were aged 35 plus when treated for severe dysplasia.

Women were twice as likely to develop invasive cervical cancer after a diagnosis of severe dysplasia if the diagnosis was made between 1991 and 2000 than between 1958 and 1970.

sanjay.tanday@haymarket.com

Comment below and tell us what you think

Comments

Only registered users may comment. Log in now or register for a free account.

There are problems with your form submission.

Please review the errors shown below.



Forgot your password?

Quick search - use * for an abbreviated search, eg nico*

 
 

Healthcare Republic Forums

 

Quick search - use * for an abbreviated search, eg nico*

 
 

Latest Clinical Articles

Abnormal uterine bleeding

Contributed by Mr Antonio V Antoniou, consultant gynaecologist and lead in minimal access surgery an... Read more

Chronic low back pain

Dr Mark Ritchie, GPSI in pain management, Morriston, Swansea Read more

Acute and sub-acute back pain

Contributed by Dr Mark Ritchie, GPSI in pain management, Morriston, Swansea Read more

Show all clinical articles

MIMS Product News

New drug - Stelara

Janssen-Cilag has launched Stelara for the treatment of moderate to severe plaque psoriasis where ot... Read more

New high-strength nicotine patch

Nicorette Invisipatch is the latest addition to the range of available nicotine replacement therapy ... Read more

Prolonged-release aspirin

Flamasacard, a prolonged-release formulation of aspirin, for secondary prophylaxis after a first cor... Read more

Jobs